Literature DB >> 33340772

An Overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand RANKL and related nutritional interventions.

Desislava Daisy Ilchovska1, Dr Michelle Barrow2.   

Abstract

Nuclear Factor Kappa-Β (NF-kB) is recognized as one of the main inflammatory pathways in the Autoimmune Disease (AD) Rheumatoid Arthritis (RA), which exhibits high levels of inflammatory cytokines such as IL-1, TNFa and IL-6 linked to bone erosion and disease progression. NF-kB is also the most studied pathophysiological mechanism in RA, however, over the last few decades, a more recently discovered Receptor Activator of Nuclear Factor Kappa-Β Ligand (RANKL), also linked to NF-kB activation and bone erosion, has been the topic of interest for research in the area of AD management. As the non-discriminative long term suppression of the NF-kB pathway by pharmacological agents in the management of RA has been linked with a number of side effects and with the discovery of the RANKL mechanism, which may present a more targeted approach to the management of the AD, there has been renewed interest in research on the potential impact of nutritional interventions influencing the NF-kB pathway, RANKL as well as RA disease outcomes. Existing research highlights the potential utility of nutrients such as Omega 3 and Vitamin D, which may lower NF-kB activation in RA. There is, however, a gap in the knowledge of the effects of nutritional interventions on pathophysiological mechanisms contributing to RA and a more robust systematic analysis of whether nutrients or specific vitamins can have an effect on the NF-kB and RANKL main drivers of pathology in RA. Findings from this study suggest the potential of Vitamin D supplementation in lowering the levels of RANKL and related markers/cytokines such as Th17 cell levels, OPG/RANKL ratio and CXCL10 pathway, which may present as a viable nutrition intervention for the management of RA. The methodology of this review involved a Systematic Search of the Literature with a Critical Appraisal of papers. It incorporated three tranche searches of 1. review, 2. animal/in vitro and 3. intervention peer reviewed research published in the last 10 years, resulting in a total of 119 papers. Results provide an overview of the NF-kB pathway, a detailed mechanistic examination of the Receptor Activator of Nuclear Factor Kappa-Β Ligand (RANKL) which is linked to bone erosion, and finally a review of nutritional interventions relating to this mechanism of pathophysiology. The accepted papers were critically appraised using SIGN50 for human studies and the ARRIVE guidelines for animal studies; the narrative was and the extracted information coded into key themes.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; NF-kB; Nutritional interventions; OPG/RANKL ratio; RANKL; Rheumatoid arthritis; Vitamin D

Mesh:

Substances:

Year:  2020        PMID: 33340772     DOI: 10.1016/j.autrev.2020.102741

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  17 in total

1.  Na-AIP-1 secreted by human hookworms suppresses collagen-induced arthritis.

Authors:  Kane Langdon; Geraldine Buitrago; Darren Pickering; Paul Giacomin; Alex Loukas; Nagaraja Haleagrahara
Journal:  Inflammopharmacology       Date:  2022-01-15       Impact factor: 4.473

Review 2.  Mitochondrial Dysfunction and Oxidative Stress in Rheumatoid Arthritis.

Authors:  María José López-Armada; Jennifer Adriana Fernández-Rodríguez; Francisco Javier Blanco
Journal:  Antioxidants (Basel)       Date:  2022-06-12

3.  Punicalagin Inhibited Inflammation and Migration of Fibroblast-Like Synoviocytes Through NF-κB Pathway in the Experimental Study of Rheumatoid Arthritis.

Authors:  Mingcheng Huang; Keping Wu; Shan Zeng; Wenfen Liu; Tianjiao Cui; Zhiqing Chen; Lian Lin; Dongying Chen; Hui Ouyang
Journal:  J Inflamm Res       Date:  2021-05-12

4.  Euphorbia factor L3 ameliorates rheumatoid arthritis by suppressing the inflammatory response by targeting Rac family small GTPase 1.

Authors:  Haojun Shi; Shufeng Li; Yun Geng; Huancai Fan; Ruojia Zhang; Yuang Zhang; Jihong Pan; Guanhua Song; Luna Ge; Tianhua Xie; Lin Wang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

5.  Zingerone (4-(four-hydroxy-3-methylphenyl) butane-two-1) modulates adjuvant-induced rheumatoid arthritis by regulating inflammatory cytokines and antioxidants.

Authors:  Nazirah Bashir; Sheikh Bilal Ahmad; Muneeb U Rehman; Showkeen Muzamil; Rahil Razak Bhat; Manzoor Ur Rahman Mir; Gamal A Shazly; Mohamed A Ibrahim; Gehan M Elossaily; Abdelrahman Y Sherif; Mohsin Kazi
Journal:  Redox Rep       Date:  2021-12       Impact factor: 4.412

6.  OX40-Fc Fusion Protein Alleviates PD-1-Fc-Aggravated Rheumatoid Arthritis by Inhibiting Inflammatory Response.

Authors:  Yanyan Huang; Shudian Lin; Feng Zhan; Lu Xiao; Yuwei Zhan; Ru Wang
Journal:  Comput Math Methods Med       Date:  2022-02-17       Impact factor: 2.238

7.  Effect of Fushengong Decoction on PTEN/PI3K/AKT/NF-κB Pathway in Rats With Chronic Renal Failure via Dual-Dimension Network Pharmacology Strategy.

Authors:  Hongyu Luo; Munan Wang; Ke Xu; Qiyao Peng; Bo Zou; Shi Yin; Chao Yu; Lingyan Ren; Ping Li; Li Tang; Yongbo Peng; Xuekuan Huang
Journal:  Front Pharmacol       Date:  2022-03-15       Impact factor: 5.810

8.  GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy.

Authors:  Shun-Wen Cheng; Po-Chih Chen; Tzong-Rong Ger; Hui-Wen Chiu; Yuan-Feng Lin
Journal:  J Pers Med       Date:  2021-03-12

Review 9.  Receptor Specificity Engineering of TNF Superfamily Ligands.

Authors:  Fengzhi Suo; Xinyu Zhou; Rita Setroikromo; Wim J Quax
Journal:  Pharmaceutics       Date:  2022-01-13       Impact factor: 6.321

10.  Efficient Treatment of Rheumatoid Arthritis by Degradable LPCE Nano-Conjugate-Delivered p65 siRNA.

Authors:  Xiaohua Chen; Bailing Zhou; Yan Gao; Kaiyu Wang; Jieping Wu; Ming Shuai; Ke Men; Xingmei Duan
Journal:  Pharmaceutics       Date:  2022-01-11       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.